Citations 4
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma
Dumke, Henry , Thiruvengadam, Swetha Kambhampati, Argao, Christine, Schroers‐Martin, Joseph G. , Lanka, Sree M , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Okcu, Izel, Nowakowski, Grzegorz S. , Doukas, Peter , Shanmugasundaram, Krithika , Colton, Meryl, Spinner, Michael A. , Rodriguez, Stefania M. , Lakin, Brock G., D’Angelo, Christopher R., Kamdar, Manali, Adewale, Olutobi, Baron, Margaret Kelsey , Bock, Allison M. , Geer, Marcus , Karimi, Yasmin , Dumke, Henry , Schroers-Martin, Joseph G , Lanka, Sree , Sawalha, Yazeed , Alharthy, Hanan , Ahmed, Sairah , Doukas, Peter G , Karmali, Reem , Shanmugasundaram, Krithika , Duvall, Adam , Pizzuti, Vincenzo J , Adewale, Olutobi , Rhodes, Joanna , Tiger, Yun Kyoung Ryu, Baron, Kelsey , Bock, Allison M , Geer, Marcus J , Karimi, Yasmin H , Yang, Xi , Thiruvengadam, Swetha Kambhampati, Karmali, Reem , Colton, Meryl D. , DuVall, Adam , D’Angelo, Christopher R. , Pizzuti, Vincenzo J. , Kamdar, Manali , Rhodes, Joanna , Tiger, Yun Kyoung
Blood Advances | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available
10.1182/bloodadvances.2026020965
Primary mediastinal B-cell lymphoma (PMBCL) is a rare form of large B-cell lymphoma (LBCL) with around 90% of patients cured with frontline treatment. For relapsed or refractory (R/R) disease, the optimal treatment is unclear. CD19 chimeric antigen receptor-T cell (CAR-T) has been established as the preferred second line (2L) treatment for primary refractory or early relapsing LBCL based on the overall survival benefits observed in the landmark phase III trials. However, PMBCL patients were underrepresented on these pivotal studies. This study evaluated outcomes of 252 patients treated with 2L therapies for R/R PMBCL at 14 US institutions between 2001 and 2025. Platinum-based salvage with intent to proceed to high dose therapy and autologous stem cell transplant (HDT/ASCT) (platinum cohort) and CD19 CAR-T (CAR-T cohort) were given as 2L therapy in the real-world setting in 157 and 26 patients, respectively. Overall response rate (ORR), complete response (CR) rate and median progression-free survival (PFS) were significantly higher in the CAR-T cohort compared with the platinum cohort (ORR: 91.3% vs 44.2%, p <0.001; CR 65.2% vs 14.7%, p<0.001; median PFS not reached vs 3.5 months, hazard ratio (HR) 0.28, 95% CI 0.15-0.54, p=0.001). No significant difference was observed in overall survival. This study demonstrated superior response rate and PFS of CD19 CAR-T over platinum-based salvage with intent to proceed to HDT/ASCT as 2L treatment for R/R PMBCL.
Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma
Baek, Grace , Varma, Gaurav, Yamshon, Samuel , Besien, Herman J van, Bartlett, Nancy L., Watkins, Marcus P. , Baron, K., Falade, Ayo , Svoboda, Jakub, Prischak, Sara, D'Angelo, C., Lukowski, Joe D., Advani, Ranjana H, Yeung, Austin, Rosenberg, Maya, Lynch, Ryan C. , Poh, Christina, Raghunathan, Vikram, Shadman, Mazyar, Smith, Stephen D. , Ujjani, Chaitra S., Bartlett, Nancy L. , Advani, Ranjana H. , Varma, Gaurav , Baron, Margaret Kelsey , van Besien, Herman , Bartlett, Nancy L , Watkins, Marcus , Baron, Kelsey , Falade, Ayo S , Prischak, Sara , D'Angelo, Christopher , Lukowski, Joe D , Di, Mengyang , Lynch, Ryan C , Poh, Christina , Shadman, Mazyar , Smith, Stephen D , Ujjani, Chaitra , Diefenbach, Catherine S , Advani, Ranjana H , Shah, Harsh R., Merryman, Reid W. , Svoboda, Jakub , Voutsinas, Jenna M. , Di, Mengyang , Raghunathan, Vikram M. , Shadman, Mazyar , Till, Brian G. , Ujjani, Chaitra S. , Diefenbach, Catherine , Gopal, Ajay K.
Blood Advances | March 19, 2026 | Volume: 10 | Issue: 10 | Pages: 3565-3571
PD-1–based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma
Desai, Sanjal H. , Moskowitz, Alison J. , Pederson, Levi , Geyer, Susan, Ganesan, Nivetha , Chang, Tiffany , Othman, Tamer , Falade, Ayo , Ng, Lay She , Baron, Margaret Kelsey , Ong, Shin Yeu , Yoon, Kevin, Ansell, Stephen M. , Armand, Philippe , Iyengar, Siddharth , Micallef, Ivana N. , Herrera, Alex F. , Pederson, Levi D , Chang, Tiffany , Othman, Tamer , Falade, Ayo S , Shah, Gunjan L , Sumransub, Nuttavut , Baron, Kelsey , Ong, Shin Yeu , Micallef, Ivana, Stuver, Robert , Herrera, Alex F , Mei, Matthew , Desai, Sanjal , Merryman, Reid W. , Shah, Harsh, Shah, Gunjan L. , Durani, Urshila , Stuver, Robert , Mei, Matthew
Blood | December 17, 2025 | Volume: 147 | Issue: 10 | Pages: 1125-1134
Abstract Combination therapy incorporating programmed cell death protein 1 (PD-1) blockade results in unprecedented response rates in both frontline and relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). Previous retrospective studies have suggested benefit for PD-1 blockade before autologous stem cell transplant (ASCT) but included few patients receiving PD-1 blockade with cytotoxic chemotherapy. To explore the impact of anti–PD-1 based salvage on outcomes for patients with R/R cHL, we retrospectively reviewed 1280 patients with R/R cHL who underwent ASCT from 2010 to 2022 at 6 transplant centers, none of whom received PD-1 blockade as part of frontline therapy. Overall, 25% received a PD-1 inhibitor at any point before ASCT (10% in conjunction with chemotherapy), 28% received salvage brentuximab vedotin (BV) without PD-1 blockade, and the rest received salvage chemotherapy alone. Patients who received PD-1 inhibitors at any point before ASCT had a significantly higher 2-year progression-free survival than those who received BV without PD-1 inhibitors or patients receiving chemotherapy alone (88.2%, 70.2%, and 67.4%, respectively; P< .0001). When restricted to patients in complete response before ASCT, the benefit of PD-1 blockade remained significant. PD-1 blockade before ASCT is independently associated with superior post-ASCT outcomes and patients proceeding to ASCT should be treated with PD-1–based salvage.
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab
Brooks, Taylor , Zabor, Emily C. , Bedelu, Yohanna B., Yang, Xi , Karimi, Yasmin , Nedved, Adrienne, Wang, Yucai , Dave, Nikita, Baron, Margaret Kelsey , Trotier, Daniel, Miller, Jordan A. , Reinert, Catherine, Schwarz, Tenley, Salafian, Kiarash , Ayers, Emily C. , McKenna, Marshall, Tiger, Yun Kyoung , Sears-Smith, Megan , Peterson, Chelsea , Khan, Cyrus, Bliven, Sean Patrick , Narkhede, Mayur , Gibson, Alyssa, Munoz, Javier, Smith, Stephen D. , Hernandez‐Ilizaliturri, Francisco J. , Chinyengetere, Fadzai, Davé, Sandeep S. , Abdel-Razeq, Nayef , Hill, Brian T. , Brooks, Taylor R , Karimi, Yasmin H , Baron, Kelsey , Trotier, Daniel C , Pophali, Priyanka , Grover, Natalie S , Major, Ajay , Salafian, Kiarash , Ayers, Emily C , Brody, Joshua D , Sears-Smith, Megan , Peterson, Chelsea , Bliven, Sean P , Garza-Morales, Rodolfo , Ho, Carrie , Smith, Stephen D , Niu, Alex , Moustafa, Muhamad Alhaj , Wang, Yucai , Landsburg, Daniel J. , Hu, Boyu , Pophali, Priyanka A. , Grover, Natalie S. , Major, Ajay , Patel, Krish , Sundaram, Suchitra , Brody, Joshua , Ghosh, Nilanjan , Kline, Justin Paul , Munoz, Javier, Garza-Morales, Rodolfo , Niu, Alex , Moustafa, Muhamad Alhaj , Caimi, Paolo F.
Blood | July 15, 2025 | Volume: 146 | Issue: 18 | Pages: 2177-2188
Abstract Epcoritamab and glofitamab are CD20-directed bispecific antibodies (BsAbs) approved in the United States for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Limited data exist for patients treated outside of trials. Patients with R/R DLBCL receiving commercial epcoritamab or glofitamab between 1 January 2023 and 15 October 2024 were collected from 21 United States institutions. Among 245 patients, 156 received epcoritamab and 89 received glofitamab, 113 were refractory to front-line therapy, 40 had MYC and BCL2 and/or BCL6 rearrangements, 147 received prior chimeric antigen receptor T-cell therapy, and 174 patients would have been ineligible for registrational trials. The overall response rate (ORR) for epcoritamab and glofitamab was 51% (23% complete response, [CR]) and 53% (30% CR), respectively. Median progression-free survival (PFS) was 2.6 months (95% confidence interval [CI], 2.0-3.8 months), and median overall survival (OS) was 7.8 months (95% CI, 6.2-11.0 months). The 6-month PFS was 36% (95% CI, 30-44) and the 6-month OS was 60% (95% CI, 54-67). Both trial ineligibility and undetectable CD20 pre-BsAbs portended shorter PFS and OS. Of 17 individuals with paired biopsies, 15 (88.2%) lost CD20 expression after BsAbs with a median time to progression of 3.7 months. This analysis including patients with R/R DLBCL shows the ORR to CD3/CD20 BsAbs was comparable to pivotal trials, although PFS and OS were lower. Baseline undetectable levels of CD20 were associated with poor outcomes. These results demonstrate the activity of BsAbs in R/R DLBCL, and underscore the importance of target antigen expression.